Julia Landin
Overview
Explore the profile of Julia Landin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landin J, Weber W, Vetter M
Ther Umsch
. 2023 Nov;
80(8):353-358.
PMID: 37971525
Breast cancer today has a significantly better prognosis than two to three decades ago. Treatment options have improved significantly. However, new systemic therapy has also resulted in side effects that...
2.
Bischof E, Schwab F, Georgescu Margarint E, Montavon C, Zunti I, Schollbach A, et al.
Bone Rep
. 2022 Jan;
16:101160.
PMID: 34977282
Aim: In patients with postmenopausal hormone receptor-positive breast cancer (ER + eBC), aromatase inhibitors (AIs) are widely used for effective relapse prevention. However, AIs reduce bone density and increase bone-related...
3.
Kopp Lugli A, Marti W, Salm L, Mujagic E, Bundi M, von Strauss M, et al.
World J Surg
. 2021 Nov;
46(2):400.
PMID: 34817622
No abstract available.
4.
Kopp Lugli A, Marti W, Salm L, Mujagic E, Bundi M, von Strauss M, et al.
World J Surg
. 2021 Nov;
46(2):391-399.
PMID: 34750659
Background: Patients with diabetes mellitus type 2 (DM2) inhere impaired peripheral insulin action leading to higher perioperative morbidity and mortality rates, with hospital-acquired infections being one important complication. This post...
5.
Szczerba B, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al.
Nature
. 2019 Feb;
566(7745):553-557.
PMID: 30728496
A better understanding of the features that define the interaction between cancer cells and immune cells is important for the development of new cancer therapies. However, focus is often given...
6.
Gkountela S, Castro-Giner F, Szczerba B, Vetter M, Landin J, Scherrer R, et al.
Cell
. 2019 Jan;
176(1-2):98-112.e14.
PMID: 30633912
The ability of circulating tumor cells (CTCs) to form clusters has been linked to increased metastatic potential. Yet biological features and vulnerabilities of CTC clusters remain largely unknown. Here, we...
7.
Vetter M, Landin J, Szczerba B, Castro-Giner F, Gkountela S, Donato C, et al.
Breast Cancer Res
. 2018 Nov;
20(1):141.
PMID: 30458879
Background: The presence of circulating tumor cells (CTCs) in patients with breast cancer correlates to a bad prognosis. Yet, CTCs are detectable in only a minority of patients with progressive...
8.
Weber W, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R, et al.
Breast Cancer Res Treat
. 2018 Sep;
172(3):523-537.
PMID: 30182349
Purpose: Indications for nipple-sparing mastectomy (NSM) have broadened to include the risk reducing setting and locally advanced tumors, which resulted in a dramatic increase in the use of NSM. The...
9.
Weber W, Mujagic E, Zwahlen M, Bundi M, Hoffmann H, Soysal S, et al.
Lancet Infect Dis
. 2017 Apr;
17(6):605-614.
PMID: 28385346
Background: Based on observational studies, administration of surgical antimicrobial prophylaxis (SAP) for the prevention of surgical site infection (SSI) is recommended within 60 min before incision. However, the precise optimum...
10.
Landin J, Weber W
Breast Care (Basel)
. 2016 Oct;
11(4):282-286.
PMID: 27721717
Axillary lymph node dissection (ALND) has been standard of care for all patients with breast cancer until the 1990s. The stepwise retreat of breast surgeons from the axilla began after...